Figure 7
Figure 7. Hypothetical model for regulation of PECAM-1 tyrosine phosphorylation and inhibitory function by PECAM-1 cytoplasmic domain interactions with the plasma membrane. (A) Schematic diagram representing membrane proximity of amino acids within the human PECAM-1 cytoplasmic domain. Amino acids are identified with the single-letter code, and numbering is based on the sequence of the mature human protein. ITIM tyrosine residues are shown in yellow, and the serine residues that are susceptible to inducible (S702) and constitutive (S707) phosphorylation in platelets are shown in orange. The juxtamembrane cytoplasmic cysteine residue that is susceptible to palmitoylation is shown in red. A segment of the PECAM-1 cytoplasmic domain that spans amino acid residues T682-S702 forms an amphipathic helix that participates in plasma membrane interactions. Important features of the membrane-interacting segment are that it (1) is bordered by the inducibly phosphorylated serine residue (S702), (2) encompasses the C-terminal ITIM tyrosine residue (Y686), and (3) excludes the N-terminal tyrosine residue (Y663). (B) Model for regulation of PECAM-1 cytoplasmic domain phosphorylation by reversible plasma membrane association. (i) In resting platelets, the PECAM-1 cytoplasmic domain, which is constitutively phosphorylated on S707, binds to the plasma membrane via interactions between hydrophobic amino acids and neutral phospholipids (gray) and between positively charged amino acids and negatively charged phospholipids (black). (ii) Activation of a serine/threonine (S/T) kinase in activated platelets results in phosphorylation of S702, which initiates dissociation of the membrane-interacting segment from the plasma membrane and exposes the C-terminal ITIM tyrosine residue (Y686). (iii) Activation of a tyrosine kinase in aggregated platelets results in phosphorylation of Y686, which enables subsequent phosphorylation of the N-terminal ITIM tyrosine residue (Y663). Phosphorylation of both ITIMs supports SHP-2 binding and PECAM-1 inhibitory function.

Hypothetical model for regulation of PECAM-1 tyrosine phosphorylation and inhibitory function by PECAM-1 cytoplasmic domain interactions with the plasma membrane. (A) Schematic diagram representing membrane proximity of amino acids within the human PECAM-1 cytoplasmic domain. Amino acids are identified with the single-letter code, and numbering is based on the sequence of the mature human protein. ITIM tyrosine residues are shown in yellow, and the serine residues that are susceptible to inducible (S702) and constitutive (S707) phosphorylation in platelets are shown in orange. The juxtamembrane cytoplasmic cysteine residue that is susceptible to palmitoylation is shown in red. A segment of the PECAM-1 cytoplasmic domain that spans amino acid residues T682-S702 forms an amphipathic helix that participates in plasma membrane interactions. Important features of the membrane-interacting segment are that it (1) is bordered by the inducibly phosphorylated serine residue (S702), (2) encompasses the C-terminal ITIM tyrosine residue (Y686), and (3) excludes the N-terminal tyrosine residue (Y663). (B) Model for regulation of PECAM-1 cytoplasmic domain phosphorylation by reversible plasma membrane association. (i) In resting platelets, the PECAM-1 cytoplasmic domain, which is constitutively phosphorylated on S707, binds to the plasma membrane via interactions between hydrophobic amino acids and neutral phospholipids (gray) and between positively charged amino acids and negatively charged phospholipids (black). (ii) Activation of a serine/threonine (S/T) kinase in activated platelets results in phosphorylation of S702, which initiates dissociation of the membrane-interacting segment from the plasma membrane and exposes the C-terminal ITIM tyrosine residue (Y686). (iii) Activation of a tyrosine kinase in aggregated platelets results in phosphorylation of Y686, which enables subsequent phosphorylation of the N-terminal ITIM tyrosine residue (Y663). Phosphorylation of both ITIMs supports SHP-2 binding and PECAM-1 inhibitory function.

Close Modal

or Create an Account

Close Modal
Close Modal